Prevalance of obesity in children with cerebral palsy

Ankita Bansal1, Shraddha Diwan2, Jasmin Diwan3

  • 11 Year MPT Neurology, Department of Pediatric Physiotherapy, S.B.B College of Physiotherapy , Ahmedabad, India .

Insights

Children with cerebral palsy (CP) show high rates of overweight and central obesity risk, as indicated by BMI and waist-to-hip ratio (WHR) measurements. This study highlights potential health risks associated with obesity in this population.

Area of Science:

  • Pediatrics
  • Public Health
  • Disability Studies

Background:

  • Childhood obesity is a growing global epidemic.
  • Cerebral palsy (CP) is a leading cause of childhood disability.
  • Existing research suggests a link between childhood disability and increased obesity risk.

Purpose of the Study:

  • To investigate the prevalence of overweight and obesity in children with cerebral palsy (CP).
  • To assess obesity trends in children with CP using Body Mass Index (BMI) and Waist-to-Hip Ratio (WHR).

Main Methods:

  • A cross-sectional study was conducted.
  • Participants included 40 children aged 2-18 years diagnosed with CP (GMFCS I-IV).
  • BMI and WHR were calculated using standard measurements and WHO growth charts.

Main Results:

  • 40% of children with CP were underweight, 45% normal weight, 7.5% overweight, and 7.5% obese based on BMI.
  • WHR indicated 20% at moderate risk and 60% at high risk of obesity.
  • Analysis revealed a significant prevalence of overweight and central obesity risk in the studied CP population.

Conclusions:

  • Children with CP exhibit a high prevalence of being overweight.
  • There is a notable risk of central obesity among children with CP.
  • Findings underscore the need for targeted weight management strategies for children with CP.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
430
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
353
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
317